SCHEMBL402253

SCHEMBL402253

COc1ccc(Cc2nc3cc(C(=O)O)ccc3c(=O)[nH]2)c(F)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.56
RECQL P46063 1/20 0.56
PDE5A O76074 1/20 0.53
POLB P06746 1/20 0.48
ENPP1 P22413 1/20 0.46
PARP14 Q460N5 1/20 0.43
MMP13 P45452 1/20 0.43
BRD4 O60885 1/20 0.43
DYRK3 O43781 1/20 0.42
DYRK1A Q13627 1/20 0.42
DYRK2 Q92630 1/20 0.42
DYRK1B Q9Y463 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.41
ALDH1A1 P00352 2/20 0.41
RAB9A P51151 2/20 0.41
HTT P42858 1/20 0.41
TUBB4A P04350 1/20 0.41
TUBB P07437 1/20 0.41
TUBA3C P0DPH7 1/20 0.41
TUBA1B P68363 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL405888 0.86 KDM4E (0.61) KDM4ERECQLPDE5APOLBPARP14
SCHEMBL404491 0.84 PDE5A (0.67) KDM4ERECQLPDE5APOLBSMN1; SMN2
SCHEMBL403999 0.84 PDE5A (0.63) KDM4ERECQLPDE5APOLBBRD4
SCHEMBL401473 0.84 KDM4E (0.64) KDM4ERECQLPDE5APOLBPARP14
SCHEMBL403044 0.83 KDM4E (0.62) KDM4ERECQLPDE5APOLBSMN1; SMN2
SCHEMBL400381 0.82 KDM4E (0.61) KDM4ERECQLPDE5APOLBSMN1; SMN2
SCHEMBL401645 0.81 PDE5A (0.72) KDM4ERECQLPDE5APOLBMMP13
SCHEMBL405002 0.80 PDE5A (0.61) KDM4ERECQLPDE5APOLBSMN1; SMN2
SCHEMBL405782 0.80 POLB (0.59) KDM4ERECQLPDE5APOLBSMN1; SMN2
SCHEMBL404586 0.80 KDM4E (0.61) KDM4ERECQLPDE5APOLBPARP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050739-B1 QUINAZOLINE DERIVATIVE ASKA PHARM CO LTD (JP) 2016-07-06 EP disclosed
US-8101624-B2 Quinazoline derivatives ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-01-24 US disclosed
US-20100113484-A1 TREATING AGENT OF UROPATHY ASKA PHARMACEUTICAL CO., LTD. (JP) 2010-05-06 US disclosed
US-20090318478-A1 QUINAZOLINE DERIVATIVES ASKA PHARMACEUTICAL CO., LTD. 2009-12-24 US disclosed
EP-2123301-A1 THERAPEUTIC AGENT FOR URINARY TRACT DISEASE ASKA Pharmaceutical Co., Ltd. (JP) 2009-11-25 EP disclosed
CN-101557826-A Therapeutic agent for urinary tract disease ASKA PHARM CO LTD (JP) 2009-10-14 CN disclosed
CN-101501007-A Quinazoline derivative ASKA PARMACEUTICAL CO LTD (JP) 2009-08-05 CN disclosed
EP-2050739-A1 QUINAZOLINE DERIVATIVE ASKA Pharmaceutical Co., Ltd. (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113484-A1 TREATING AGENT OF UROPATHY BPHL, PDE12, UROD KDM4E 4291/4885RECQL 878/4885PDE5A 14/4885
US-20090318478-A1 QUINAZOLINE DERIVATIVES PDE9A, PDE3A, PDE5A KDM4E 2869/4885RECQL 100/4885PDE5A 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.